Abstract

* Epclusa, an oral, fixed-dose combination drug containing sofosbuvir and velpatasvir, is the first agent approved to treat all six variants of the hepatitis C genotype. * It is prescribed as monotherapy if the patient has compensated (mild) cirrhosis or no cirrhosis and as combination therapy with ribavirin if the patient has decompensated cirrhosis.